acrivastine/pseudoephedrine (Rx)

Brand and Other Names:Semprex-D

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

acrivastine/pseudoephedrine

capsule

  • 8mg/60mg

Seasonal Allergic Rhinitis or Nasal Congestion

8 mg/60 mg (1 capsule) PO q4-6h

>14 days continuous treatment efficacy not adequately investigated

Renal Impairment

CrCl>48mL/min: Dose adjustment not necessary

CrCl <48mL/min: Not recommended

Hepatic Impairment

Not studied

Dosage Forms & Strengths

acrivastine/pseudoephedrine

capsule

  • 8mg/60mg

Seasonal Allergic Rhinitis or Nasal Congestion

<12 years: Safety and efficacy not established

>12 years: 8 mg/60 mg (1 capsule) PO q4-6h

>14 days continuous treatment efficacy not adequately investigated

Next:

Interactions

Interaction Checker

and acrivastine/pseudoephedrine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (16)

            • dihydroergotamine

              dihydroergotamine increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Ergot derivatives may enhance the vasoconstricting effect of pseudoephedrine and eventually significantly increasing blood pressure.

            • dihydroergotamine inhaled

              dihydroergotamine inhaled increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Ergot derivatives may enhance the vasoconstricting effect of pseudoephedrine and eventually significantly increasing blood pressure.

            • dihydroergotamine intranasal

              dihydroergotamine intranasal increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Ergot derivatives may enhance the vasoconstricting effect of pseudoephedrine and eventually significantly increasing blood pressure.

            • ergoloid mesylates

              ergoloid mesylates increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Ergot derivatives may enhance the vasoconstricting effect of pseudoephedrine and eventually significantly increasing blood pressure.

            • ergonovine

              ergonovine increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Ergot derivatives may enhance the vasoconstricting effect of pseudoephedrine and eventually significantly increasing blood pressure.

            • ergotamine

              ergotamine increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Ergot derivatives may enhance the vasoconstricting effect of pseudoephedrine and eventually significantly increasing blood pressure.

            • isocarboxazid

              isocarboxazid increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

            • linezolid

              linezolid increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

            • methylergonovine

              methylergonovine increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Ergot derivatives may enhance the vasoconstricting effect of pseudoephedrine and eventually significantly increasing blood pressure.

            • phenelzine

              phenelzine increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

            • procarbazine

              procarbazine increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

            • rasagiline

              rasagiline increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

            • selegiline

              selegiline increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

            • selegiline transdermal

              selegiline transdermal increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

            • thalidomide

              acrivastine and thalidomide both increase sedation. Contraindicated.

            • tranylcypromine

              tranylcypromine increases effects of pseudoephedrine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

            Serious - Use Alternative (51)

            • alfentanil

              acrivastine and alfentanil both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • amisulpride

              amisulpride and acrivastine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • amitriptyline

              amitriptyline increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • amoxapine

              amoxapine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • benzhydrocodone/acetaminophen

              acrivastine and benzhydrocodone/acetaminophen both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • buprenorphine

              acrivastine and buprenorphine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • buprenorphine buccal

              acrivastine and buprenorphine buccal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • buprenorphine subdermal implant

              acrivastine and buprenorphine subdermal implant both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

              buprenorphine subdermal implant and acrivastine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • buprenorphine transdermal

              acrivastine and buprenorphine transdermal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • buprenorphine, long-acting injection

              acrivastine and buprenorphine, long-acting injection both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • cabergoline

              cabergoline, pseudoephedrine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.

            • clomipramine

              clomipramine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • cocaine topical

              cocaine topical increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug.

            • codeine

              acrivastine and codeine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • desipramine

              desipramine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • desvenlafaxine

              desvenlafaxine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug.

            • deutetrabenazine

              acrivastine and deutetrabenazine both increase sedation. Avoid or Use Alternate Drug.

            • doxapram

              doxapram increases effects of pseudoephedrine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive pressor effect.

            • doxepin

              doxepin increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • duloxetine

              duloxetine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug.

            • fentanyl

              acrivastine and fentanyl both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • fentanyl intranasal

              acrivastine and fentanyl intranasal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • fentanyl iontophoretic transdermal system

              acrivastine and fentanyl iontophoretic transdermal system both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • fentanyl transdermal

              acrivastine and fentanyl transdermal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • fentanyl transmucosal

              acrivastine and fentanyl transmucosal both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • hydrocodone

              acrivastine and hydrocodone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • hydromorphone

              acrivastine and hydromorphone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • imipramine

              imipramine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • iobenguane I 123

              pseudoephedrine decreases effects of iobenguane I 123 by receptor binding competition. Avoid or Use Alternate Drug. If clinically appropriate, discontinue drugs that compete for NE receptor sites for at least 5 half-lives; may cause false-negative imaging results. Do not administer pseudoephedrine until at least 7 days after each iobenguane dose.

            • iobenguane I 131

              pseudoephedrine decreases effects of iobenguane I 131 by receptor binding competition. Avoid or Use Alternate Drug. If clinically appropriate, discontinue drugs that compete for NE receptor sites for at least 5 half-lives; may cause false-negative imaging results. Do not administer pseudoephedrine until at least 7 days after each iobenguane dose.

            • isoflurane

              isoflurane increases toxicity of pseudoephedrine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.

            • levomilnacipran

              levomilnacipran increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug.

            • lofepramine

              lofepramine, pseudoephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • maprotiline

              maprotiline, pseudoephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • methadone

              acrivastine and methadone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • methocarbamol

              acrivastine and methocarbamol both increase sedation. Avoid or Use Alternate Drug.

            • methoxyflurane

              methoxyflurane increases toxicity of pseudoephedrine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.

            • metoclopramide intranasal

              acrivastine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

            • milnacipran

              milnacipran increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug.

            • morphine

              acrivastine and morphine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • nortriptyline

              nortriptyline increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • oxycodone

              acrivastine and oxycodone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • oxymorphone

              acrivastine and oxymorphone both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate

            • ozanimod

              ozanimod increases toxicity of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.

            • protriptyline

              protriptyline increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • selinexor

              selinexor, acrivastine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.

            • sevoflurane

              sevoflurane increases toxicity of pseudoephedrine by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.

            • tramadol

              acrivastine and tramadol both increase sedation. Avoid or Use Alternate Drug.

            • trazodone

              trazodone, pseudoephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            • triazolam

              acrivastine and triazolam both increase sedation. Avoid or Use Alternate Drug.

            • trimipramine

              trimipramine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.

            Monitor Closely (220)

            • acetaminophen/phenyltoloxamine

              acrivastine and acetaminophen/phenyltoloxamine both increase sedation. Use Caution/Monitor.

            • acetazolamide

              acetazolamide will increase the level or effect of pseudoephedrine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor.

            • albuterol

              albuterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • alfuzosin

              pseudoephedrine decreases effects of alfuzosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • alprazolam

              acrivastine and alprazolam both increase sedation. Use Caution/Monitor.

            • aluminum hydroxide

              aluminum hydroxide will increase the level or effect of pseudoephedrine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor. Caution advised with frequent or high dose antacids

            • amisulpride

              acrivastine and amisulpride both increase sedation. Use Caution/Monitor.

            • amitriptyline

              acrivastine and amitriptyline both increase sedation. Use Caution/Monitor.

            • ammonium chloride

              ammonium chloride decreases effects of pseudoephedrine by unknown mechanism. Use Caution/Monitor. Urinary excretion of indirect acting alpha/beta agonists (eg, pseudoephedrine) may increase when administered concomitantly with urinary acidifying agents, resulting in lower serum concentrations.

            • amobarbital

              acrivastine and amobarbital both increase sedation. Use Caution/Monitor.

            • amoxapine

              acrivastine and amoxapine both increase sedation. Use Caution/Monitor.

            • arformoterol

              arformoterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • aripiprazole

              acrivastine and aripiprazole both increase sedation. Use Caution/Monitor.

            • asenapine

              acrivastine and asenapine both increase sedation. Use Caution/Monitor.

            • asenapine transdermal

              acrivastine and asenapine transdermal both increase sedation. Use Caution/Monitor.

            • avapritinib

              acrivastine and avapritinib both increase sedation. Use Caution/Monitor.

            • baclofen

              acrivastine and baclofen both increase sedation. Use Caution/Monitor.

            • benzphetamine

              benzphetamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • brexanolone

              brexanolone, acrivastine. Either increases toxicity of the other by sedation. Use Caution/Monitor.

              acrivastine and brexanolone both increase sedation. Use Caution/Monitor.

            • brexpiprazole

              acrivastine and brexpiprazole both increase sedation. Use Caution/Monitor.

            • brimonidine

              acrivastine and brimonidine both increase sedation. Use Caution/Monitor.

            • brivaracetam

              acrivastine and brivaracetam both increase sedation. Use Caution/Monitor.

            • bromocriptine

              bromocriptine, pseudoephedrine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach.

            • brompheniramine

              acrivastine and brompheniramine both increase sedation. Use Caution/Monitor.

            • butabarbital

              acrivastine and butabarbital both increase sedation. Use Caution/Monitor.

            • butalbital

              acrivastine and butalbital both increase sedation. Use Caution/Monitor.

            • butorphanol

              acrivastine and butorphanol both increase sedation. Use Caution/Monitor.

            • carbinoxamine

              acrivastine and carbinoxamine both increase sedation. Use Caution/Monitor.

            • cariprazine

              acrivastine and cariprazine both increase sedation. Use Caution/Monitor.

            • carisoprodol

              acrivastine and carisoprodol both increase sedation. Use Caution/Monitor.

            • cenobamate

              cenobamate, acrivastine. Either increases effects of the other by sedation. Use Caution/Monitor.

              acrivastine and cenobamate both increase sedation. Use Caution/Monitor.

            • cetirizine

              acrivastine and cetirizine both increase sedation. Use Caution/Monitor.

            • chlordiazepoxide

              acrivastine and chlordiazepoxide both increase sedation. Use Caution/Monitor.

            • chlorpheniramine

              acrivastine and chlorpheniramine both increase sedation. Use Caution/Monitor.

            • chlorpromazine

              chlorpromazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.

              acrivastine and chlorpromazine both increase sedation. Use Caution/Monitor.

            • chlorzoxazone

              acrivastine and chlorzoxazone both increase sedation. Use Caution/Monitor.

            • dexfenfluramine

              dexfenfluramine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • clemastine

              acrivastine and clemastine both increase sedation. Use Caution/Monitor.

            • clobazam

              acrivastine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

              acrivastine and clobazam both increase sedation. Use Caution/Monitor.

            • clomipramine

              acrivastine and clomipramine both increase sedation. Use Caution/Monitor.

            • clonazepam

              acrivastine and clonazepam both increase sedation. Use Caution/Monitor.

            • clonidine

              acrivastine and clonidine both increase sedation. Use Caution/Monitor.

            • clorazepate

              acrivastine and clorazepate both increase sedation. Use Caution/Monitor.

            • clozapine

              acrivastine and clozapine both increase sedation. Use Caution/Monitor.

            • cyclobenzaprine

              acrivastine and cyclobenzaprine both increase sedation. Use Caution/Monitor.

            • cyproheptadine

              acrivastine and cyproheptadine both increase sedation. Use Caution/Monitor.

            • dantrolene

              acrivastine and dantrolene both increase sedation. Use Caution/Monitor.

            • daridorexant

              acrivastine and daridorexant both increase sedation. Use Caution/Monitor.

            • desflurane

              acrivastine and desflurane both increase sedation. Use Caution/Monitor.

            • desipramine

              acrivastine and desipramine both increase sedation. Use Caution/Monitor.

            • dexbrompheniramine

              acrivastine and dexbrompheniramine both increase sedation. Use Caution/Monitor.

            • dexchlorpheniramine

              acrivastine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

            • dexmethylphenidate

              dexmethylphenidate and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • dextroamphetamine

              dextroamphetamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • diazepam

              acrivastine and diazepam both increase sedation. Use Caution/Monitor.

            • diethylpropion

              diethylpropion and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • difenoxin hcl

              acrivastine and difenoxin hcl both increase sedation. Use Caution/Monitor.

            • dimenhydrinate

              acrivastine and dimenhydrinate both increase sedation. Use Caution/Monitor.

            • diphenhydramine

              acrivastine and diphenhydramine both increase sedation. Use Caution/Monitor.

            • diphenoxylate hcl

              acrivastine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.

            • dobutamine

              dobutamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • dopamine

              dopamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • dopexamine

              dopexamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • doxazosin

              pseudoephedrine decreases effects of doxazosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • doxepin

              acrivastine and doxepin both increase sedation. Use Caution/Monitor.

            • doxylamine

              acrivastine and doxylamine both increase sedation. Use Caution/Monitor.

            • droperidol

              acrivastine and droperidol both increase sedation. Use Caution/Monitor.

            • droxidopa

              pseudoephedrine and droxidopa both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. May increase risk for supine hypertension

            • efavirenz

              acrivastine and efavirenz both increase sedation. Use Caution/Monitor.

            • entacapone

              acrivastine and entacapone both increase sedation. Use Caution/Monitor.

            • ephedrine

              ephedrine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              ephedrine, pseudoephedrine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.

            • epinephrine

              epinephrine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • epinephrine inhaled

              pseudoephedrine, epinephrine inhaled. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • epinephrine racemic

              epinephrine racemic and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • esketamine intranasal

              esketamine intranasal, acrivastine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

              esketamine intranasal, pseudoephedrine. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. .

              acrivastine and esketamine intranasal both increase sedation. Use Caution/Monitor.

            • estazolam

              acrivastine and estazolam both increase sedation. Use Caution/Monitor.

            • fenfluramine

              fenfluramine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • eszopiclone

              acrivastine and eszopiclone both increase sedation. Use Caution/Monitor.

            • ethanol

              acrivastine and ethanol both increase sedation. Use Caution/Monitor.

            • ethosuximide

              acrivastine and ethosuximide both increase sedation. Use Caution/Monitor.

            • ethotoin

              acrivastine and ethotoin both increase sedation. Use Caution/Monitor.

            • felbamate

              acrivastine and felbamate both increase sedation. Use Caution/Monitor.

            • fenfluramine

              acrivastine and fenfluramine both increase sedation. Use Caution/Monitor.

            • fexofenadine

              acrivastine and fexofenadine both increase sedation. Use Caution/Monitor.

            • flibanserin

              acrivastine and flibanserin both increase sedation. Use Caution/Monitor.

            • fluphenazine

              acrivastine and fluphenazine both increase sedation. Use Caution/Monitor.

              fluphenazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.

            • flurazepam

              acrivastine and flurazepam both increase sedation. Use Caution/Monitor.

            • formoterol

              formoterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • gabapentin

              acrivastine and gabapentin both increase sedation. Use Caution/Monitor.

            • ganaxolone

              acrivastine and ganaxolone both increase sedation. Use Caution/Monitor.

            • guanfacine

              acrivastine and guanfacine both increase sedation. Use Caution/Monitor.

            • haloperidol

              acrivastine and haloperidol both increase sedation. Use Caution/Monitor.

            • hydralazine

              hydralazine, pseudoephedrine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Sympathomimetics can antagonize the activity of some antihypertensive agents.

            • hydroxyzine

              acrivastine and hydroxyzine both increase sedation. Use Caution/Monitor.

            • iloperidone

              acrivastine and iloperidone both increase sedation. Use Caution/Monitor.

            • imipramine

              acrivastine and imipramine both increase sedation. Use Caution/Monitor.

            • insulin degludec

              pseudoephedrine decreases effects of insulin degludec by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Sympathomimetics increase blood glucose by stimulating alpha and beta receptors; this action results in increased hepatic glucose production, glycogenolysis, and decreased insulin secretion.

            • insulin degludec/insulin aspart

              pseudoephedrine decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Sympathomimetics increase blood glucose by stimulating alpha and beta receptors; this action results in increased hepatic glucose production, glycogenolysis, and decreased insulin secretion.

            • insulin detemir

              pseudoephedrine decreases effects of insulin detemir by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Sympathomimetics increase blood glucose by stimulating alpha and beta receptors; this action results in increased hepatic glucose production, glycogenolysis, and decreased insulin secretion.

            • insulin glargine

              pseudoephedrine decreases effects of insulin glargine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Sympathomimetics increase blood glucose by stimulating alpha and beta receptors; this action results in increased hepatic glucose production, glycogenolysis, and decreased insulin secretion.

            • insulin inhaled

              pseudoephedrine decreases effects of insulin inhaled by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Sympathomimetics increase blood glucose by stimulating alpha and beta receptors; this action results in increased hepatic glucose production, glycogenolysis, and decreased insulin secretion.

            • insulin regular human

              pseudoephedrine decreases effects of insulin regular human by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Sympathomimetics increase blood glucose by stimulating alpha and beta receptors; this action results in increased hepatic glucose production, glycogenolysis, and decreased insulin secretion.

            • isoflurane

              acrivastine and isoflurane both increase sedation. Use Caution/Monitor.

            • isoproterenol

              isoproterenol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • ketamine

              acrivastine and ketamine both increase sedation. Use Caution/Monitor.

            • ketotifen, drug-eluting contact lens

              acrivastine and ketotifen, drug-eluting contact lens both increase sedation. Use Caution/Monitor.

            • lamotrigine

              acrivastine and lamotrigine both increase sedation. Use Caution/Monitor.

            • lasmiditan

              acrivastine and lasmiditan both increase sedation. Use Caution/Monitor.

            • lemborexant

              lemborexant, acrivastine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects. .

              acrivastine and lemborexant both increase sedation. Use Caution/Monitor.

            • levalbuterol

              levalbuterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • levetiracetam

              acrivastine and levetiracetam both increase sedation. Use Caution/Monitor.

            • levocetirizine

              acrivastine and levocetirizine both increase sedation. Use Caution/Monitor.

            • levorphanol

              acrivastine and levorphanol both increase sedation. Use Caution/Monitor.

            • lisdexamfetamine

              lisdexamfetamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • loratadine

              acrivastine and loratadine both increase sedation. Use Caution/Monitor.

            • lorazepam

              acrivastine and lorazepam both increase sedation. Use Caution/Monitor.

            • loxapine

              acrivastine and loxapine both increase sedation. Use Caution/Monitor.

            • lumateperone

              acrivastine and lumateperone both increase sedation. Use Caution/Monitor.

            • lurasidone

              lurasidone, acrivastine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

              acrivastine and lurasidone both increase sedation. Use Caution/Monitor.

            • maprotiline

              acrivastine and maprotiline both increase sedation. Use Caution/Monitor.

            • meclizine

              acrivastine and meclizine both increase sedation. Use Caution/Monitor.

            • meperidine

              acrivastine and meperidine both increase sedation. Use Caution/Monitor.

            • meprobamate

              acrivastine and meprobamate both increase sedation. Use Caution/Monitor.

            • metaproterenol

              metaproterenol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • metaxalone

              acrivastine and metaxalone both increase sedation. Use Caution/Monitor.

            • methamphetamine

              methamphetamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • methenamine

              methenamine decreases effects of pseudoephedrine by unknown mechanism. Use Caution/Monitor. Urinary excretion of indirect acting alpha/beta agonists (eg, pseudoephedrine) may increase when administered concomitantly with urinary acidifying agents, resulting in lower serum concentrations.

            • methohexital

              acrivastine and methohexital both increase sedation. Use Caution/Monitor.

            • methsuximide

              acrivastine and methsuximide both increase sedation. Use Caution/Monitor.

            • methyldopa

              methyldopa increases effects of pseudoephedrine by unknown mechanism. Use Caution/Monitor.

            • methylenedioxymethamphetamine

              methylenedioxymethamphetamine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • midazolam

              acrivastine and midazolam both increase sedation. Use Caution/Monitor.

            • midazolam intranasal

              midazolam intranasal, acrivastine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

            • midodrine

              midodrine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • mirtazapine

              acrivastine and mirtazapine both increase sedation. Use Caution/Monitor.

            • molindone

              acrivastine and molindone both increase sedation. Use Caution/Monitor.

            • nalbuphine

              acrivastine and nalbuphine both increase sedation. Use Caution/Monitor.

            • nateglinide

              pseudoephedrine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.

            • nitrous oxide

              acrivastine and nitrous oxide both increase sedation. Use Caution/Monitor.

            • norepinephrine

              norepinephrine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • nortriptyline

              acrivastine and nortriptyline both increase sedation. Use Caution/Monitor.

            • olanzapine

              acrivastine and olanzapine both increase sedation. Use Caution/Monitor.

            • oliceridine

              acrivastine increases toxicity of oliceridine by Other (see comment). Use Caution/Monitor. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.

              acrivastine and oliceridine both increase sedation. Use Caution/Monitor.

            • olodaterol inhaled

              pseudoephedrine and olodaterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Caution with coadministration of adrenergic drugs by any route because of additive sympathetic effects

            • olopatadine intranasal

              acrivastine and olopatadine intranasal both increase sedation. Use Caution/Monitor.

            • opicapone

              acrivastine and opicapone both increase sedation. Use Caution/Monitor.

            • opium tincture

              acrivastine and opium tincture both increase sedation. Use Caution/Monitor.

            • orphenadrine

              acrivastine and orphenadrine both increase sedation. Use Caution/Monitor.

            • oxazepam

              acrivastine and oxazepam both increase sedation. Use Caution/Monitor.

            • oxytocin

              oxytocin increases effects of pseudoephedrine by pharmacodynamic synergism. Use Caution/Monitor.

            • paliperidone

              acrivastine and paliperidone both increase sedation. Use Caution/Monitor.

            • pentazocine

              acrivastine and pentazocine both increase sedation. Use Caution/Monitor.

            • pentobarbital

              acrivastine and pentobarbital both increase sedation. Use Caution/Monitor.

            • perampanel

              acrivastine and perampanel both increase sedation. Use Caution/Monitor.

            • perphenazine

              acrivastine and perphenazine both increase sedation. Use Caution/Monitor.

              perphenazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.

            • phendimetrazine

              phendimetrazine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • pheniramine

              acrivastine and pheniramine both increase sedation. Use Caution/Monitor.

            • phenobarbital

              acrivastine and phenobarbital both increase sedation. Use Caution/Monitor.

            • phentermine

              phentermine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • phenylephrine

              phenylephrine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • phenylephrine PO

              phenylephrine PO and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • pimozide

              acrivastine and pimozide both increase sedation. Use Caution/Monitor.

            • pirbuterol

              pirbuterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • pomalidomide

              acrivastine and pomalidomide both increase sedation. Use Caution/Monitor.

            • potassium phosphate

              potassium phosphate decreases effects of pseudoephedrine by unknown mechanism. Use Caution/Monitor. Urinary excretion of indirect acting alpha/beta agonists (eg, pseudoephedrine) may increase when administered concomitantly with urinary acidifying agents, resulting in lower serum concentrations.

            • pregabalin

              acrivastine and pregabalin both increase sedation. Use Caution/Monitor.

            • primidone

              acrivastine and primidone both increase sedation. Use Caution/Monitor.

            • prochlorperazine

              acrivastine and prochlorperazine both increase sedation. Use Caution/Monitor.

              prochlorperazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.

            • promazine

              promazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • promethazine

              acrivastine and promethazine both increase sedation. Use Caution/Monitor.

            • promethazine

              promethazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.

            • propofol

              acrivastine and propofol both increase sedation. Use Caution/Monitor.

            • propylhexedrine

              propylhexedrine and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • protriptyline

              acrivastine and protriptyline both increase sedation. Use Caution/Monitor.

            • pyrilamine

              acrivastine and pyrilamine both increase sedation. Use Caution/Monitor.

            • quazepam

              acrivastine and quazepam both increase sedation. Use Caution/Monitor.

            • quetiapine

              acrivastine and quetiapine both increase sedation. Use Caution/Monitor.

            • ramelteon

              acrivastine and ramelteon both increase sedation. Use Caution/Monitor.

            • remifentanil

              acrivastine and remifentanil both increase sedation. Use Caution/Monitor.

            • remimazolam

              acrivastine and remimazolam both increase sedation. Use Caution/Monitor.

            • reserpine

              acrivastine and reserpine both increase sedation. Use Caution/Monitor.

            • risperidone

              acrivastine and risperidone both increase sedation. Use Caution/Monitor.

            • safinamide

              pseudoephedrine and safinamide both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Monitor patients for hypertension if safinamide is prescribed concomitantly with prescription or nonprescription sympathomimetics, including nasal, oral, or ophthalmic decongestants and cold remedies.

            • salmeterol

              salmeterol and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • scopolamine

              acrivastine and scopolamine both increase sedation. Use Caution/Monitor.

            • serdexmethylphenidate/dexmethylphenidate

              serdexmethylphenidate/dexmethylphenidate and pseudoephedrine both decrease sedation. Use Caution/Monitor.

              serdexmethylphenidate/dexmethylphenidate and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • sevoflurane

              acrivastine and sevoflurane both increase sedation. Use Caution/Monitor.

            • silodosin

              pseudoephedrine decreases effects of silodosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • sodium bicarbonate

              sodium bicarbonate will increase the level or effect of pseudoephedrine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor. Caution advised with frequent or high dose antacids

            • sodium citrate/citric acid

              sodium citrate/citric acid will increase the level or effect of pseudoephedrine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor.

            • sodium lactate

              sodium lactate will increase the level or effect of pseudoephedrine by passive renal tubular reabsorption - basic urine. Use Caution/Monitor.

            • sodium oxybate

              acrivastine and sodium oxybate both increase sedation. Use Caution/Monitor.

            • sodium phosphates, IV

              sodium phosphates, IV decreases effects of pseudoephedrine by unknown mechanism. Use Caution/Monitor. Urinary excretion of indirect acting alpha/beta agonists (eg, pseudoephedrine) may increase when administered concomitantly with urinary acidifying agents, resulting in lower serum concentrations.

            • solriamfetol

              pseudoephedrine and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • spironolactone

              spironolactone decreases effects of pseudoephedrine by pharmacodynamic antagonism. Use Caution/Monitor.

            • stiripentol

              stiripentol, acrivastine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

              acrivastine and stiripentol both increase sedation. Use Caution/Monitor.

            • sufentanil

              acrivastine and sufentanil both increase sedation. Use Caution/Monitor.

            • sufentanil SL

              acrivastine and sufentanil SL both increase sedation. Use Caution/Monitor.

            • suvorexant

              acrivastine and suvorexant both increase sedation. Use Caution/Monitor.

            • tamsulosin

              pseudoephedrine decreases effects of tamsulosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • tapentadol

              acrivastine and tapentadol both increase sedation. Use Caution/Monitor.

            • tasimelteon

              acrivastine and tasimelteon both increase sedation. Use Caution/Monitor.

            • temazepam

              acrivastine and temazepam both increase sedation. Use Caution/Monitor.

            • terazosin

              pseudoephedrine decreases effects of terazosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • terbutaline

              terbutaline and pseudoephedrine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • tetrabenazine

              acrivastine and tetrabenazine both increase sedation. Use Caution/Monitor.

            • thioridazine

              acrivastine and thioridazine both increase sedation. Use Caution/Monitor.

              thioridazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.

            • thiothixene

              acrivastine and thiothixene both increase sedation. Use Caution/Monitor.

            • trifluoperazine

              trifluoperazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.

            • tiagabine

              acrivastine and tiagabine both increase sedation. Use Caution/Monitor.

            • tizanidine

              acrivastine and tizanidine both increase sedation. Use Caution/Monitor.

            • tolcapone

              acrivastine and tolcapone both increase sedation. Use Caution/Monitor.

            • topiramate

              acrivastine and topiramate both increase sedation. Use Caution/Monitor.

            • trazodone

              acrivastine and trazodone both increase sedation. Use Caution/Monitor.

            • trifluoperazine

              acrivastine and trifluoperazine both increase sedation. Use Caution/Monitor.

            • triprolidine

              acrivastine and triprolidine both increase sedation. Use Caution/Monitor.

            • valproic acid

              acrivastine and valproic acid both increase sedation. Use Caution/Monitor.

            • vigabatrin

              acrivastine and vigabatrin both increase sedation. Use Caution/Monitor.

            • xylometazoline

              pseudoephedrine and xylometazoline both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • zaleplon

              acrivastine and zaleplon both increase sedation. Use Caution/Monitor.

            Minor (1)

            • desmopressin

              desmopressin increases effects of pseudoephedrine by pharmacodynamic synergism. Minor/Significance Unknown.

            Previous
            Next:

            Adverse Effects

            1-10%

            Somnolence

            Nervousness

            Insomnia

            Dry mouth

            <1%

            Headache

            Dizziness

            Asthenia

            Nausea

            Dyspepsia

            Pharyngitis

            Cough increase

            Dysmenorrhea

            Postmarketing Reports

            Rare serious hypersensitivity reactions manifested by anaphylaxis, angioedema, bronchospasm, and erythema multiforme

            Pseudoephedrine

            • Tachycardia
            • Palpitations
            • Serious skin reactions (acute generalized exanthematous pustulosis)
            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to acrivastine or other alkylamine antihistamines

            Hypersensitivity to pseudoephedrine or other sympathomimetic amines

            Severe hypertension

            Severe coronary artery disease

            Patients taking monoamine oxidase (MAO) inhibitors and for 14 days after stopping use of an MAO inhibitor

            Cautions

            Due to potential for sedation, assess individual responses before engaging in any activity requiring mental alertness, such as driving a motor vehicle or operating machinery

            Concurrent use with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of CNS performance and should be avoided

            Not adequately studied for relieving common cold symptoms

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: Unknown whether acrivastine is distributed in breast milk, caution advised ; pseudoephedrine is excreted in human milk, caution advised

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Acrivastine exhibits H1-antihistaminic receptor activity, which prevents histamine from binding to its receptor in target cells

            Pseudoephedrine: Indirect sympathomimetic agent, releases norepinephrine from adrenergic nerves

            Half-Life

            Acrivastine 1.9-3.5 hr; propionic acid metabolite 3.8 hrs

            Pseudoephedrine 5-8 hr

            Absorption

            Rapid and complete

            Vd

            Acrivastine 0.46 L/kg

            Pseudoephedrine 3 L/kg

            Peak Plasma Time

            Acrivastine 1.1 hr

            Pseudoephedrine 1.97 hr

            Peak Plasma Concentration

            Acrivastine 227 ng/ml

            Pseudoephedrine 422 ng/ml

            Protein Bound

            Acrivastine 50%

            Pseudoephedrine minimal

            Metabolism

            Acrivastine 11% to propionic acid metabolite

            Clearance

            Acrivastine 2.9 mL/min/kg

            Pseudoephedrine 5.9 mL/min/kg

            Excretion

            Acrivastine: feces (13%) urine (84%)

            Pseudoephedrine: 55-75% renal (dependent on urine pH)

            Previous
            Next:

            Images

            No images available for this drug.
            Previous
            Next:

            Patient Handout

            A Patient Handout is not currently available for this monograph.
            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.